These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8814705)

  • 1. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.
    Klaassen U; Wilke H; Strumberg D; Eberhardt W; Korn M; Seeber S
    Eur J Cancer; 1996 Mar; 32A(3):547-9. PubMed ID: 8814705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical phase I study with one-hour paclitaxel infusion.
    Mross K; Hauns B; Häring B; Bauknecht T; Meerpohl HG; Unger C; Maier-Lenz H
    Ann Oncol; 1998 May; 9(5):569-72. PubMed ID: 9653500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
    du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
    Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
    Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M
    J Clin Oncol; 1995 Dec; 13(12):2961-7. PubMed ID: 8523061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
    Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study.
    Lombardi D; Crivellari D; Scuderi C; Magri MD; Spazzapan S; Sorio R; Di Lauro V; Scalone S; Veronesi A
    Tumori; 2004; 90(3):285-8. PubMed ID: 15315306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.
    Soulié P; Trandafir L; Taamma A; Lokiec F; Brain E; Delord JP; Mita A; Vannetzel JM; Cvitkovic E; Misset JL
    Anticancer Drugs; 1997 Sep; 8(8):763-6. PubMed ID: 9396620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
    Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
    J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel activity in anthracycline refractory breast cancer patients.
    Vici P; Di Lauro L; Conti F; Capomolla E; Gionfra T; Amodio A; Lopez M
    Tumori; 1997; 83(3):661-4. PubMed ID: 9267484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
    Tsavaris N; Polyzos A; Kosmas C; Giannikos L; Gogas J
    Cancer Chemother Pharmacol; 1997; 40(4):353-7. PubMed ID: 9225955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
    J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.